Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
29 December 2025
Financial statements and reports, Regulated information

ANNEX IX DECEMBER 2025 Open in new window

29 September 2025
Financial statements and reports

HALF-YEAR FINANCIAL REPORT JUNE 2025 Open in new window

22 September 2025
Financial statements and reports

ANNEX IX Open in new window

01 July 2025
Financial statements and reports, Regulated information

ANNEX IX Open in new window

08 April 2025
Financial statements and reports, Regulated information

URD 2024 Open in new window

26 September 2024
Financial statements and reports

2024 HALF-YEAR FINANCIAL REPORT Open in new window

07 May 2024
Financial statements and reports, Regulated information

AMENDMENT TO THE 2023 UNIVERSAL REGISTRATION DOCUMENT Open in new window

17 April 2024
Financial statements and reports

2023 Universal Registration Document Open in new window

18 September 2023
Financial statements and reports

2023 HALF-YEAR FINANCIAL REPORT Open in new window

14 June 2023
Financial statements and reports, General Assembly, General meetings

Statutory auditors’ supplementary report dated 25 January 2022 Open in new window

  • 1
  • 2
  • 3
  • 4
  • View next 9 articles
© 2026 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page